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The acute coronary syndromes (ACS), with or without ST-segment elevation, share a
common pathophysiology of activated platelets and thrombin generation stimulated by plaque
erosion and rupture. Both mechanical and pharmacologic treatment strategies have evolved in
an attempt to improve reperfusion at the myocardial tissue level. Intracoronary stents have
lowered the incidence of abrupt vessel closure and restenosis, while potent platelet inhibition
from intravenous glycoprotein IIb/IIIa antagonists has reduced the rate of periprocedural
myocardial infarction and late mortality. Abciximab has well-established clinical benefits in
percutaneous revascularization trials, and several recent landmark studies have evaluated the
efficacy of concomitant abciximab during mechanical reperfusion therapy in the setting of
ACS. These trials are reviewed, and an overall perspective is provided. (J Am Coll Cardiol
2003;41:49S–54S) © 2003 by the American College of Cardiology Foundation
The acute coronary syndromes (ACS) refer to a continuum
of pathological, clinical, and outcome features associated
with unstable angina, non–ST-segment elevation myocar-
dial infarction (MI), and ST-segment elevation MI (1). At
the site of an unstable atherosclerotic lesion, endothelial
erosion or plaque rupture occurs with subsequent coronary
thrombus formation (2,3). Central to the pathogenesis of
ACS is platelet activation and aggregation. The interaction
between activated platelets and thrombin forms a potent
collaborating mechanism leading to the dynamic propaga-
tion of a thrombus.
The benefits of reperfusion therapy during acute MI
include early achievement of arterial patency, limiting to the
size of infarction, a decrease in left ventricular dysfunction,
and improved survival (4–9). Timely restoration of normal
antegrade flow and tissue-level perfusion are key factors in
the reduction of mortality in acute MI (10,11). Both
fibrinolytic therapy and emergent percutaneous coronary
intervention (PCI) have contributed to improved clinical
outcomes (12), but each has its limitations and is not an
ideal reperfusion therapy by itself. Facilitated angioplasty is
an approach in which adjunctive fibrinolytic therapy or a
platelet glycoprotein (GP) IIb/IIIa receptor blocker is given
minutes in advance of emergent PCI to optimize patency,
reperfusion, and early clinical outcomes. Indeed, by contrast
with the inferior clinical results of most immediate-
angioplasty post-fibrinolysis strategies (13), the incorpora-
tion of GP IIb/IIIa inhibitors into early reperfusion therapy
may provide and maintain an anti-thrombotic milieu in
which pharmacologic or mechanical reperfusion therapy can
be performed more safely and effectively.
Among patients with non–ST-segment elevation ACS,
the combinations of aspirin plus either unfractionated hep-
arin or low-molecular-weight heparin have been recom-
mended for initial management by standard guidelines (14).
The antiplatelet effect of aspirin, however, is rather modest.
Recent trial data, in fact, show that clopidogrel added to
aspirin reduces a composite of death, recurrent MI, and
stroke by 20% in the early months after presentation with an
ACS (15). For intermediate and high-risk patients, espe-
cially those with an ACS (16–20), and among patients
undergoing PCI (21), GP IIb/IIIa inhibitors provide addi-
tional protection against recurrent ischemia. Neither phar-
macologic lysis nor primary coronary stenting alone can fully
address the issues that affect clinical outcome after ACS: a
platelet-rich thrombogenic milieu, residual arterial stenosis,
and distal embolization. Although both pharmacologic
(aspirin and heparin) and mechanical (PCI) approaches can
improve ACS outcome, the vascular injury associated with
the syndrome and PCI results in further activation of
platelets and thrombus formation, and it increases the risk
of re-occlusion. Thus, by inhibiting the GP IIb/IIIa recep-
tors, the final common pathway of platelet aggregation,
platelet deposition, thrombin generation, and distal embo-
lization from the disrupted arterial surface can be attenu-
ated. Over the past decade, with over 25,000 patients
enrolled in PCI trials testing GP IIb/IIIa inhibitors, these
agents have been shown to reduce the risk of death and
non-fatal MI by approximately 35% at 30 days (22–30).
Abciximab. Abciximab is a monoclonal antibody that
strongly binds the GP IIb/IIIa integrin on platelets, thereby
blocking the binding of fibrinogen, its primary ligand.
Abciximab also binds to v3 (vitronectin) receptors on
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smooth muscle cells and may inhibit M2 receptors located
on granulocytes and monocytes (31). Thus, in addition to
platelet aggregation inhibition and de-thrombosis, abcix-
imab may reduce inflammation and smooth muscle cell
proliferation. Although abciximab binds to receptors for an
average of 14 days, effective platelet aggregation inhibition
lasts for approximately 36 h after cessation of infusion due
to redistribution and clearance of the antibody (32). Animal
studies correlated 80% GP IIb/IIIa receptor occupancy with
efficacy in thrombosis prevention (33), and a subsequent
study defined the clinical weight-adjusted dose, correlating
this level of occupancy with 80% platelet aggregation
inhibition (up to 20 M adenosine diphosphate) (34).
Pharmacologic combinations. The key limitations to the
widespread use of primary PCI strategies for acute MI are
attributable to the lack of available catheterization labora-
tories and the inherent time delays in initiating the proce-
dure (prolonged door-to-balloon time) (10,11). These lim-
itations have led to the continued search for an ideal
thrombolytic strategy that would provide a high rate of early
Thrombolysis In Myocardial Infarction grade 3 (TIMI-3)
flow. Several trials have been performed assessing a combi-
nation pharmacologic approach, and although these were
designed as medical therapy trials and not with an intent-
to-stent approach, they do provide mechanistic insight into
the benefit of abciximab for patients with ST-elevation MI.
Compared with plasminogen activator monotherapy, early
studies (Glycoprotein Receptor Antagonist Patency Evalu-
ation [GRAPE], Strategies for Patency Enhancement in
the Emergency Department [SPEED], TIMI-14) (35–37)
demonstrated that a combination of low-dose plasminogen
activator (tPA or rPA) and abciximab provided more rapid
and complete myocardial reperfusion based on TIMI flow
rates at 60 to 90 min. The GUSTO V trial (38) studied
half-dose reteplase plus full-dose abciximab compared with
full-dose reteplase in an open-label design among patients
presenting with ST-elevation MI. At 30 days, the all-cause
mortality was similar between the two groups (5.6% for the
reteplase plus abciximab group, 5.9% for the reteplase
group; p 0.43) (38) (Fig. 1). However, recurrent ischemia
and re-infarction, as well as the need for coronary interven-
tion, were significantly lower in the reteplase plus abciximab
group. The reduction of vessel re-occlusion (recurrent isch-
emia or re-infarction) demonstrates the importance of
activated platelets in acute MI, despite successful initial
recanalization and the benefit of platelet IIb/IIIa blockade.
The results are likely to be applicable to the facilitated PCI
or intent-to-stent approach.
Abciximab as an adjunct to primary PCI in ST-segment
elevation MI. Primary PCI has been considered an effec-
tive alternative for re-establishing coronary perfusion, being
successful in90% of patients (39–41). With intracoronary
stent placement, primary PCI results in larger arterial
lumen, less re-occlusion of the infarct-related artery, and
fewer subsequent ischemic events, compared with balloon
angioplasty alone (42–47). Recently, Stone et al. (48)
reported the predictive value of myocardial blush score for
30-day mortality after PCI (Fig. 2), which highlights the
importance of perfusion at the myocardial tissue level. The
strategy of incorporating abciximab with PCI is designed to
achieve a more effective initial reperfusion and to maintain
an anti-thrombotic milieu, even downstream at the tissue
level.
Abbreviations and Acronyms
ADP  adenosine diphosphate
ACS  acute coronary syndrome(s)
GP  glycoprotein
HR  hazard ratio
MI  myocardial infarction
PA  plasminogen activator
PCI  percutaneous coronary intervention
TVR  target vessel revascularization
Figure 1. Primary and secondary end points at 30 days in the Global Use
of Strategies to Open Occluded Arteries in Acute Coronary Syndromes V
trial. Recorded on day 7 or at discharge, whichever was earlier. MI 
myocardial infarction; PCI  percutaneous coronary intervention. Re-
printed with permission from Elsevier Science (Lancet 2001;357:1905–14).
Figure 2. Association of myocardial blush (microvascular perfusion) and
mortality among myocardial infarction patients with Thrombolysis In
Myocardial Infarction grade 3 flow undergoing emergent percutaneous
transluminal coronary angioplasty. Adapted with permission from the
American College of Cardiology Foundation, J Am Coll Cardiol 2000;35:
403A.
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Because abciximab reduces the 30-day composite end
point of death, MI, and urgent revascularization with
balloon angioplasty for acute MI (49), and stenting reduces
abrupt vessel closure and restenosis (50), the combination of
stent and abciximab is logical. In the Stent-Primary Angio-
plasty in Myocardial Infarction (Stent-PAMI) trial (50),
stent placement was associated with lower clinical and
angiographic restenosis rates. However, among patients
treated with stents, there tended to be a lower incidence of
TIMI grade 3 flow (89.4% vs. 92.7%; p  0.10), absence of
improvement of left ventricular ejection fraction, and more
importantly, a suggestion of increased mortality at six
months (4.3% vs. 3.5%) and at one year (5.8% vs. 3.1%).
To consider the complementary role of abciximab and
stenting in acute MI, the Controlled Abciximab and Device
Investigation to Lower Late Angioplasty Complications
(CADILLAC) (51) trial randomized 2,665 acute MI pa-
tients from 92 centers in North America, South America,
and Europe, using a 22 factorial study design: stent plus
abciximab, percutaneous transluminal coronary angioplasty
plus abciximab, stent plus placebo, and angioplasty alone.
At six months, the primary composite end point (death,
re-MI, urgent target vessel revascularization [TVR], or
stroke) was reduced by half with stent placement, compared
with angioplasty (10.9% vs. 19.3%; p  0.008). At 30 days,
cumulative subacute thrombosis was lower with abciximab
after either angioplasty (reduced from 1.7% to 0.6%; p 
0.07) or stent placement (1.0% to 0%; p  0.03). Notably,
abciximab did not offer a clinical benefit among stent
recipients (Fig. 3), nor was the post-procedural TIMI grade
3 flow improved with abciximab. These findings may have
been affected by a potentially lower-risk MI population
enrolled in this study, as reflected by the much lower
mortality rate when compared with other primary PCI
trials.
The Abciximab before Direct angioplasty and stenting in
Myocardial Infarction Regarding Acute and Long-term
follow-up (ADMIRAL) study (52) tested the effect of
abciximab in primary stenting for acute MI. The 30-day
composite end point of death, MI, or urgent TVR was
reduced from 14.6% to 6.0% with abciximab compared with
placebo (relative risk, 0.41; 95% confidence interval [CI],
0.18 to 0.93; p0.01) (Fig. 3). This benefit was sustained at
six months. Importantly, the investigators linked the rela-
tionship of TIMI 3 flow with clinical outcome among acute
MI patients undergoing primary stenting. The incidence of
TIMI 3 flow was significantly higher among the abciximab
group both before (16.8% vs. 5.4%; p 0.01) and at the end
of the procedure (95.1% vs. 86.7%; p  0.04) (Fig. 4). The
presence of post-procedural TIMI 3 flow was strongly
associated with a lower incidence of composite end points at
30 days (7.4% with TIMI 3 vs. 35.3% for TIMI 0 to 2; p 
0.001), similar to the observations from the Stent-PAMI
trial (50), SPEED trial (53), and Stone et al. (48). Mortality
at six months was also significantly correlated with post-
procedural TIMI 3 flow (2.3% with TIMI 3 vs. 17.6% with
TIMI 0 to 2; p  0.001).
The use of abciximab in PCI-stent for non–ST-segment
elevation ACS: EPISTENT and TARGET. There are
differences among the three commercially available GP
IIb/IIIa inhibitors and in the extent of relative risk reduc-
tion of ischemic events provided by these agents in PCI
trials. For example, approximately 75% of the abciximab
dose is in the bolus given immediately before PCI, whereas
10% of the dose of small-molecule agents is given as
Figure 3. Death, re-infarction, or urgent target vessel revascularization
(TVR) at 30 days using adjunctive abciximab for percutaneous coronary
intervention in acute myocardial infarction (MI) trials. Open bars 
placebo; closed bars  abciximab. ADMIRAL  Abciximab before
Direct angioplasty and stenting in Myocardial Infraction Regarding Acute
and Long-term follow-up trial; CADILLAC  Controlled Abciximab
and Device Investigation to Lower Late Angioplasty Complications trial;
ISAR  Intracoronary Stenting and Antithrombotic Regimen trial;
PTCA  percutaneous transluminal coronary angioplasty; RAPPORT 
ReoPro And Primary PTCA Organization and Randomized Trial.
Figure 4. Achievement of Thrombolysis In Myocardial Infarction (TIMI)
3 flow with abciximab in Abciximab before Direct angioplasty and stenting
in Myocardial Infraction Regarding Acute and Long-term follow-up
(ADMIRAL) trial. Open bars  placebo; closed bars  abciximab.
Adapted with permission, 2002, from Montalescot G, Barragan P, Wit-
tenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary
stenting for acute myocardial infarction. N Engl J Med 2001;334:1895–
903. Copyright 2001 Massachusetts Medical Society. All rights reserved.
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bolus. This may affect the consistency and extent of platelet
aggregation inhibition in the early minutes after drug
administration and during the PCI. Eptifibatide, like ab-
ciximab, provides inhibition of both IIb3 and v3 recep-
tors; (54) tirofiban, on the other hand, demonstrates exclu-
sive specificity toward IIb3 receptor and has a shorter
biological half-life.
In the Evaluation of Platelet IIb/IIIa Inhibition in
Stenting (EPISTENT) trial (28), the first large-scale clin-
ical study to evaluate a combination of stent placement and
abciximab administration, 2,399 patients were enrolled; 782
had unstable angina or an MI within the previous several
days. Patients were randomized to abciximab plus balloon
angioplasty, stent plus placebo, or stent plus abciximab. At
30-day follow-up, compared with placebo, abciximab had
reduced by more than half the composite of death, MI, and
urgent TVR among the recent ACS subgroup receiving a
stent. At six-month follow-up, the composite rate of death
or MI was 12.6% in the stent plus placebo group and 5.0%
in the stent plus abciximab group (p  0.002). As impres-
sive, at one-year follow-up, abciximab reduced mortality in
this ACS-stent cohort by 61% (2.3% vs. 0.9%).
The most recent large-scale clinical trial among intent-
to-stent patients, the do Tirofiban And Reopro Give similar
Efficacy outcome Trial (TARGET) (55) randomized 4,809
patients to either tirofiban (10 g/kg bolus plus 0.15
g/kg/min for 18 to 24 h) or abciximab (0.25 g/kg plus
0.125 g/kg/min). This study included 3,025 patients who
underwent PCI-stent as treatment for an ACS. While this
trial was designed as a non-inferiority trial for tirofiban, a
significant increase of the composite end point of death, MI,
or urgent TVR was associated with tirofiban at 30 days
(7.6% vs. 6.0%; hazard ratio [HR], 1.26; p  0.038). The
benefit of abciximab was most profound among the ACS
patients (death/MI/TVR at 30 days, 6.3% for abciximab vs.
9.3% for tirofiban; HR, 1.49; 95% CI, 1.15 to 1.93), and
this was sustained at six months. Considering the composite
of death, MI, and any TVR at six months, the HR for
tirofiban tended to be higher (HR; 1.19, p  0.056). These
results from TARGET, especially considering the results of
the upstream benefit of tirofiban among ACS-PCI patients
in Platelet Receptor inhibition for Ischemic Syndrome
Management in Patients Limited to very Unstable Signs
and Symptoms (PRISM-PLUS) (17) and Treat Angina
with Aggrastat and determine Cost of Therapy with Inva-
sive or Conservative Strategy-Thrombolysis In Myocardial
Infarction (TACTICS TIMI)-18 trials (56), raise more
questions about the appropriate choice of GP IIb/IIIa
agents for management of ACS and the timing coordina-
tion for subsequent PCI. The results of published trials in
non–ST-segment elevation ACS indicate that, among
intermediate-to-high-risk patients who are not proceeding
without delay to the catheterization laboratory for urgent
PCI, upstream therapy with a small molecule GP IIb/IIIa
agent (tirofiban or eptifibatide) should be initiated. For high
risk, non–ST-segment elevation ACS patients who are
proceeding to catheter-based intervention immediately with
the intent to stent, abciximab appears to confer greater
clinical benefit when combined with early PCI.
Conclusions. Large-scale clinical trial evidence over the
last decade has demonstrated, unquestionably, that abcix-
imab plays an important and beneficial role in PCI patients,
and this is evident among ACS subgroups in intent-to-stent
trials. For ST-segment elevation MI, a strategy of interven-
tional procedure with stents and adjunctive abciximab has
been shown to be the reperfusion modality of choice when
experienced operators and laboratory personnel are available
in a timely manner. This approach was shown to be superior
to standard thrombolytic therapy in STOP-AMI and supe-
rior to direct PCI-stent without abciximab in ADMIRAL.
Dual therapy of low-dose reteplase and abciximab is safe
and effective as shown in GUSTO-V, but because mortality
rates did not differ from standard thrombolytic strategies,
this approach is not likely to be competitive with a direct
PCI strategy. Abciximab added to combination lytic ap-
proaches should be avoided in the elderly (age 75 years)
and among patients who are being treated with streptoki-
nase.
The current standard of therapy for moderate-to-high-
risk non–ST-segment elevation ACS should include the
administration of tirofiban or eptifibatide beginning soon
after hospitalization, if immediate PCI is not planned.
Because most of the benefits shown in the clinical trials were
derived from the complementary use of PCI and intrave-
nous GP IIb/IIIa antagonists, all but low-risk patients
should undergo early cardiac catheterization for further risk
stratification and possible revascularization while receiving
the GP IIb/IIIa inhibitor infusion. Abciximab should be
administered to ACS patients who are taken immediately to
the catheterization laboratory or who are not already receiv-
ing a IIb/IIIa inhibitor before a planned PCI. Among
patients undergoing primary coronary intervention, abcix-
imab remains the reference standard of GP IIb/IIIa inhib-
itor initiated in the catheterization laboratory, though with
an increased cost.
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